{"id":63253,"date":"2026-04-15T22:39:13","date_gmt":"2026-04-15T14:39:13","guid":{"rendered":"https:\/\/flcube.com\/?p=63253"},"modified":"2026-04-15T22:39:14","modified_gmt":"2026-04-15T14:39:14","slug":"gan-lee-pharmaceuticals-doses-first-patient-in-phase-iii-trial-for-novel-long-acting-insulin-gzr33-in-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63253","title":{"rendered":"Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes"},"content":{"rendered":"\n

Gan & Lee Pharmaceuticals<\/strong> (SHA: 603087<\/a>) announced the first subject dosing<\/strong> in a Phase III clinical study<\/strong> in China for GZR33<\/strong>, its proprietary once-daily, long-acting basal insulin<\/strong> for type 2 diabetes (T2D)<\/strong>, marking a critical milestone in the company’s strategy to challenge established global insulin franchises with an innovative pharmacological profile.<\/p>\n\n\n\n

Clinical Development Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Gan & Lee Pharmaceuticals (SHA: 603087)<\/td><\/tr>
Study Phase<\/strong><\/td>Phase III<\/td><\/tr>
Geographic Focus<\/strong><\/td>China<\/td><\/tr>
Product<\/strong><\/td>GZR33 \u2013 once-daily long-acting basal insulin<\/td><\/tr>
Indication<\/strong><\/td>Type 2 diabetes (T2D)<\/td><\/tr>
Development Status<\/strong><\/td>First patient dosed<\/td><\/tr>
Origin<\/strong><\/td>Independently developed by Gan & Lee<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Differentiation<\/h2>\n\n\n\n

GZR33<\/strong> represents a next-generation basal insulin designed to address limitations of current long-acting insulins, with specific advantages over insulin degludec (Novo Nordisk’s Tresiba)<\/strong>:<\/p>\n\n\n\n

Pharmacological Parameter<\/th>GZR33 Advantage<\/th>Clinical Benefit<\/th><\/tr><\/thead>
Time to Peak Concentration<\/strong><\/td>Prolonged<\/td>Reduced hypoglycemia risk<\/td><\/tr>
Peak-to-Trough Ratio<\/strong><\/td>Lower<\/td>More consistent glucose control<\/td><\/tr>
Plasma Concentration<\/strong><\/td>More stable<\/td>Predictable glycemic response<\/td><\/tr>
Duration of Effect<\/strong><\/td>Longer<\/td>Enhanced 24-hour coverage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The optimized pharmacological profile is designed to deliver long-acting and stable blood glucose control<\/strong> with potentially improved safety and convenience compared to existing basal insulins.<\/p>\n\n\n\n

Strategic Market Rationale<\/h2>\n\n\n\n

China Diabetes Landscape<\/h3>\n\n\n\n